Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Virtual Reality Education Before CyberKnife Treatment for Prostate Cancer

6. november 2026 oppdatert av: University Hospital Ostrava

Virtual Doctor's Assistant: A Study of Virtual Reality Education Before Treatment to Improve Understanding in Patients With Prostate Cancer Undergoing CyberKnife Radiotherapy

This randomized controlled study evaluates virtual reality education for men aged 40 to 80 years with prostate cancer who are scheduled for CyberKnife radiotherapy at the University Hospital Ostrava. Participants are assigned in a 1:1 ratio to standard patient education alone or standard education supplemented by the Virtual Doctor's Assistant. The virtual environment reproduces the CyberKnife treatment room and explains the equipment, the treatment process, and the importance of consistent bladder and rectal preparation. The study aims to reduce stress before treatment and improve patients' understanding of the procedure and preparation requirements. Cancer treatment itself is unchanged. Outcomes will be assessed using patient questionnaires.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Patients preparing for radiotherapy need to understand both the treatment procedure and the steps they should take before each treatment session. For prostate radiotherapy, consistent bladder and rectal filling is an important component of treatment preparation. Unfamiliarity with the treatment room and equipment may also contribute to stress before the first irradiation.

The Virtual Doctor's Assistant is a virtual reality (VR) educational system developed to supplement the information provided by the treating physician. Using a VR headset, participants enter a computer-generated representation of the CyberKnife treatment room. A virtual doctor introduces the main components of the equipment, explains the treatment process, and demonstrates how preparation affects the anatomical relationships between the prostate, bladder, and rectum.

Men with prostate cancer scheduled for CyberKnife radiotherapy at University Hospital Ostrava will be assigned at random to one of two groups, with an equal probability of receiving standard education alone or standard education supplemented by VR. The radiotherapy procedure will follow standard clinical practice in both groups. Participation is voluntary, and participants may discontinue the VR experience or withdraw from the study.

The study will compare patient-reported psychological well-being and understanding of treatment and preparation requirements between the groups All measurements will be conducted using standardized collection protocols and under consistent environmental and procedural conditions to ensure reproducibility and comparability of data.

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Lukáš Knybel, Assoc.Prof., Ing., Ph.D.
  • Telefonnummer: 2125 +42059737
  • E-post: lukas.knybel@fno.cz

Studiesteder

  • Tsjekkia
    • Moravian-Silesian Region
      • Ostrava, Moravian-Silesian Region, Tsjekkia, 708 52
        • Rekruttering
        • University Hospital Ostrava
        • Ta kontakt med:
        • Ta kontakt med:
          • Lukáš Knybel, Assoc.Prof., Ing., Ph.D.
          • Telefonnummer: 2125 +42059737
          • E-post: lukas.knybel@fno.cz
        • Hovedetterforsker:
          • Lukáš Knybel, Assoc.Prof., Ing., Ph.D.
        • Underetterforsker:
          • Andrea Šoltisová, Bc.
        • Underetterforsker:
          • David Pakizer, Mgr., Ph.D.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  • Male patients aged 40 to 80 years
  • Diagnosis of prostate cancer
  • Indication for CyberKnife SBRT at the Oncology Department of University Hospital Ostrava
  • Written informed consent to participate in the study

Exclusion Criteria:

  • Not signing the informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: VR-assisted education

Study subjects randomised in this arm will receive VR-assisted education.
Annen: VR-assisted education

VR-assisted education will be provided for study subjects randomised in this intervention group.

Fremgangsmåte: Stereotactic radiosurgery

Stereotactic radiosurgery is a non-surgical radiation therapy that uses precisely focused beams of high-dose radiation to treat small tumors, lesions, or functional abnormalities
Aktiv komparator: Standard education

Study subjects randomised in this arm will receive standard education.
Fremgangsmåte: Stereotactic radiosurgery

Stereotactic radiosurgery is a non-surgical radiation therapy that uses precisely focused beams of high-dose radiation to treat small tumors, lesions, or functional abnormalities

Annen: Standard education

Standard education will be provided for study subjects randomised in this intervention group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Understanding of CyberKnife radiotherapy and preparation requirements
Tidsramme: On Day 1 of the treatment - after completion of patient education and before the first irradiation

The primary outcome measure is to assess and compare patients' understanding of CyberKnife radiotherapy and preparation requirements between the VR-assisted education group and the standard education group. Understanding will be assessed using the five-item knowledge test in Part 2 of the study-specific questionnaire. Each correct answer will receive one point, yielding a total score from 0 to 5, with higher scores indicating better understanding. The questions cover the treatment schedule, bladder and rectal preparation, the importance of consistent anatomical conditions, the consequences of inadequate preparation, and cooperation during irradiation.
On Day 1 of the treatment - after completion of patient education and before the first irradiation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient-reported clarity of education and perceived understanding
Tidsramme: On Day 1 of the treatment - after completion of patient education and before the first irradiation

Patients' perceptions of the clarity of the information provided, their ability to anticipate the first irradiation, and their understanding of preparation requirements will be assessed using Part 1 of the questionnaire. Four items are rated on a five-point agreement scale, from 1 (strongly agree) to 5 (strongly disagree), with lower scores indicating more favourable responses. A separate three-category item assesses whether patients perceive their understanding to have improved following education. Responses will be compared between groups and analysed separately.
On Day 1 of the treatment - after completion of patient education and before the first irradiation
Patient-reported psychological responses before the first irradiation
Tidsramme: Before the first CyberKnife treatment fraction

Current stress, concerns about the treatment room experience, and confidence in knowing what to expect during treatment will be assessed using the three separate numerical rating scales in Part 3 of the questionnaire. Each item is rated from 0 to 10. Higher scores indicate greater stress, greater concerns, and greater confidence, respectively. Each item will be analysed separately and compared between groups.
Before the first CyberKnife treatment fraction
Patient-reported usefulness and tolerability of VR education
Tidsramme: Before the first CyberKnife treatment fraction, referring to the preceding VR education session

Part 4 of the questionnaire will assess the VR group's perceptions of how VR helped them visualise the treatment room, understand treatment and preparation requirements, and reduce concerns. Willingness to recommend VR education will also be assessed. These four items use a five-point agreement scale, from 1 (strongly agree) to 5 (strongly disagree). A separate categorical item records discomfort experienced during VR use, including nausea, dizziness, or other symptoms. Responses will be analysed descriptively within the VR group.
Before the first CyberKnife treatment fraction, referring to the preceding VR education session
Adequacy of patient preparation and treatment workflow
Tidsramme: Before the 1st fraction

Patient preparation will be evaluated indirectly by assessing prostate position on pre-treatment X-ray images acquired before each CyberKnife treatment fraction. Prostate localisation will be based on implanted fiducial markers. Deviations from the planned reference position will be recorded and compared between the VR-assisted education group and the standard education group.
Before the 1st fraction

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

University Hospital Ostrava

Etterforskere

  • Hovedetterforsker: Lukáš Knybel, Assoc.Prof., Ing., Ph.D., University Hospital Ostrava

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. august 2026

Primær fullføring (Antatt)

1. august 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

6. november 2026

Først lagt ut (Faktiske)

12. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • FNO-ONK-VDA

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

There is no plan to make individual participant data accessible, the data may be provided upon reasonable request.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere